coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Runcorn PCN, Halton (LAD) · Health Inequalities Profile

    PCN U09643 · NHS Cheshire and Merseyside Integrated Care Board · 6 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    67,260

    Registered population

    61.3% aged 18–64

    19.1%

    Aged 65+

    ICB 19.0% · England 17.9%

    3.6%

    Ethnic minority (non-White)

    1.1% Asian · England 9.6%

    50.7%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~35,431

    Core20 residents (est.)

    Resident basis; registered basis ~34,109 · see page 3

    12,139

    Hypertension register

    +5.31% in 3 yrs · England +5.60%

    682

    SMI register

    52.1% of Halton (LAD)'s

    2,421

    COPD register

    Reviews +8.49% in 3 yrs

    Forecast to 2030

    13,582

    Hypertension patients, 2030

    +1,443 on today

    70.5%

    QRISK ≥20% on statins, 2030

    +2.78pp over 3 yrs

    5.2%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    64.0%
    Asthma review coverage trails England across large register.

    Across 5,342 asthma patients (8.3% prevalence vs England 6.6%), 64.0% had an annual review (England 65.7%), leaving about 1,900 unreviewed, which may reflect recall.

    +0.6%
    Hypertension target growth and statin reach lag England.

    Three-year hypertension treatment to target rose +0.6% (England +3.6%) and diabetes primary-prevention statins reached 66.7% (England 73.2%), which could reflect review or escalation delays.

    +26.7%
    Heart failure and mental health checks outpace England.

    Heart failure reviews rose +26.7% over three years to 82.8% (England 78.5%), while mental health BMI recording rose +12.1 pp (England +5.1 pp).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    An older age profile of 19.1% pairs with substantial borough inclusion caseloads

    Across 67,260 registered patients, 19.1% (12,839) are aged 65+, exceeding Halton (LAD) (17.5%), matching NHS Cheshire and Merseyside ICB (19.0%), and above England (17.9%). Projected list growth to 2030 is 0.9% against 1.0% in Halton (LAD), 2.3% in the ICB, and 2.3% in England (unverified methodology). Census usual-resident estimates indicate 96.4% White ethnicity compared to 96.5% in Halton (LAD), 93.0% in the ICB, and 81.1% in England, reflecting a 3.6% ethnic minority population.

    Age profile

    0–1719.6%
    18–6461.3%
    65+19.1%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White96.4%
    Mixed1.5%
    Asian1.1%
    Other0.7%
    Black0.4%

    Older people · falls rows are Halton (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Halton LA)2,1942,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)83.4%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)55.4%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Halton LA)1,1201,0219552024/25
    Falls deaths, all ages, per 100,000 (Halton LA)21.718.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 areas house 50.7% of registered patients, varying widely across member practices

    Across RUNCORN PCN, 50.7% of registered patients live in Core20 areas, exceeding Halton (LAD) (44.7%), the ICB (31.9%) and England (21.0%), with an average IMD decile of 3.7 (England 5.5). Concentration spans 42.8 pp, from 27.2% at Tower House Practice to 70.0% at Weaver Vale Practice. Castlefields Health Centre carries the highest volume with 10,267 estimated Core20 patients (65.8% share). Resident Core20 estimates (35,431) and registered patient lists use different bases. Targeting interventions purely by practice deprivation rate risks leaving the largest absolute Core20 cohort underserved.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Weaver Vale70.0% · 6,009 patients
    Brookvale68.2% · 5,876 patients
    Castlefields65.8% · 10,267 patients
    Murdishaw48.8% · 3,781 patients
    Grove House33.6% · 4,804 patients
    Tower House27.2% · 3,372 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    682

    SMI register

    1.00% recorded prevalence

    489

    Learning disability register

    0.71% recorded prevalence

    9

    Care homes, 293 beds

    In the PCN catchment

    11.3%

    Provide unpaid care

    Halton (LAD), Census 2021

    The PCN records 682 patients with severe mental illness (52.1% of the borough register) and 489 with learning disabilities (52% of the borough register; 0.7% prevalence versus Halton (LAD) 0.7%, the ICB 0.6%, and England 0.6%), alongside 9 catchment care homes with 293 beds. Holding over half the borough's recorded caseload across both registers represents a substantial primary care workload to sustain.

    Severe mental illness: physical health checks

    SMI prevalence is 1.0% (England 1.0%). For physical health checks, blood pressure review reaches 82.8% (England 83.4%), BMI recording reaches 82.9% (England 82.1%), and alcohol status recording reaches 79.8% (England 81.8%).

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    12,139

    Hypertension register

    +5.31%

    Register growth, 3 yrs

    Halton (LAD) +6.68% · England +5.60%

    +0.51pp

    BP control, under 80

    ≤140/90 · +1.08pp aged 80+

    +1,443

    More patients by 2030

    Forecast 13,582 (19.66%)

    Hypertension case-finding and control

    Runcorn PCN records 12,139 patients on its hypertension register, representing 17.7% prevalence, matching Halton (LAD) (17.7%) and above England (15.2%). While blood pressure recording reaches 89.1% (England 90.0%) and treatment to target reaches 70.0% (England 70.3%), three-year progress trailed England in recording (+0.9% versus +3.6%) and treatment to threshold (+0.6% versus +3.6%). Trailing three-year progress across 12,139 hypertensive patients suggests routine blood pressure monitoring and titration could be prioritised to prevent plateauing control.

    Lipids and statins

    Statin treatment for diabetes primary prevention sits at 66.7%, trailing Halton (LAD) (68.5%), the ICB (72.4%) and England (73.2%), alongside 2,412 adult lipid-modifying items prescribed per 1,000 (England 4,100). Lower primary-prevention statin coverage than in England suggests an under-served diabetic cohort where proactive cardiovascular reviews could be prioritised.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026130,463£1.80£1.71£1.86£234,833
    Cardiovascular (all), 2025187,006£4.25£4.37£3.33£794,776

    In 2026, the PCN prescribed 130,463 lipid-modifying items at £1.80 per item (spend £234,833), against £1.87 in Halton (LAD), £1.71 in the ICB and £1.86 in England. This was £7,828 less than at England's unit cost, but £11,742 more than at NHS Cheshire and Merseyside ICB's unit cost.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +6.73%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +1.28%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 8.3% (5,342 patients; England 6.6%) and management prescribing is 2,628 items per 1,000 aged 5-19 (England 1,488). Annual reviews reach 64.0% (England 65.7%), leaving about 1,900 patients unreviewed. COPD prevalence is 3.5% (2,421 patients; England 1.9%) with reviews reaching 76.8% (England 76.4%). High youth prescribing alongside lower review coverage could reflect recall gaps to test by auditing practice call-recall lists.

    Cancer register and children's immunisation

    Cancer prevalence is 4.2% (2,875 patients; England 3.8%). In childhood immunisations, MMR dose 1 at age 5 reaches 96.2% (England 91.7%), but dose 2 drops 5 pp to 91.2% (England 82.8%), sitting below the 95.0% target by 3.8 pp. Pre-school 4-in-1 booster reaches 90.6%. This drop between doses could reflect recall timing to test by reviewing practice call-recall lists.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months90.1%

    England 91.0%

    6-in-1 complete primary course at 24 months92.2%

    England 92.2%

    MMR dose 1 at 24 months90.3%

    England 88.3%

    MMR dose 2 at age 591.2%

    England 82.8%

    4-in-1 pre-school booster at age 590.6%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers were diagnosed at stage 1 or 2 (7,482 of 13,490 known-stage cases), sitting 19.5 pp below the 75.0% national ambition by 2028, in line with England (55.3%). Staging was recorded for 72.8% of 18,522 registered cancers. Early-stage share increased 2.6 pp from 52.8% in 2013, requiring about 2,640 extra early diagnoses annually across the ICB to reach 75.0%. Runcorn PCN cancer prevalence reached 4.2% (2,875 patients), rising +10.8% over three years (England +9.0%), while breast screening coverage (+5.0%) trailed England (+8.4%). Staging reflects wider system diagnostics rather than PCN performance, but strengthening primary care screening uptake supports earlier referral.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026 (provisional), North Cheshire and Mersey NHS Foundation Trust achieved 83.7% on the 62-day referral to treatment standard, 1.3 pp below the 85.0% standard, but exceeding NHS Cheshire and Merseyside Integrated Care Board (76.2%), Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%) and England (71.2%). The trust met the 28-day faster diagnosis standard at 80.2% (standard 75.0%) and 31-day combined standard at 98.2% (standard 96.0%). Patients waiting 6+ weeks were 0.0% for non-obstetric ultrasound and 0.5% for Magnetic Resonance Imaging. These provider metrics reflect acute system access rather than dedicated PCN performance.

    Pathways within standard (%)North Cheshire and MerseyMersey and West LancashireLiverpoolCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)80.2172.3975.4777.2579.32
    31-day treatment (96%)98.1795.4690.5195.7192.50
    62-day referral to treatment (85%)83.6777.9673.2676.2371.16
    Diagnostic waits over 6 weeks (%)North Cheshire and MerseyMersey and West LancashireLiverpoolEngland
    MRI0.5314.046.4221.40
    CT2.3213.080.719.92
    Echocardiography28.0434.8812.5528.48
    Colonoscopy15.9818.0433.1430.83
    Gastroscopy20.2418.1744.9929.02
    All 15 DM01 tests6.3421.1711.5023.14
    Community services activityHalton residentsCheshire and Merseyside ICB
    Care contacts19,830541,280
    Referrals3,18597,150
    Patients with a contact6,225146,240

    Community services (residents of Halton), Jun 2026 (provisional). In the provisional Jun 2026 Community Services Dataset, 57.1% of community contacts for Halton borough residents were with adults aged 65 and over (11,325 of 19,830 total contacts). These data describe borough resident activity rather than PCN-level patient contacts, highlighting high community care volume among older people across the local authority.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    In 2025/26, QOF clinical achievement was 88.2% at Murdishaw, while Grove House Practice achieved 100.0%. Across England, the clinical achievement comparator was 97.1%. For vaccination and immunisation, Murdishaw achieved 28.5%, whereas Grove House Practice achieved 81.3%, spanning a range of 52.8 pp. The England comparator for vaccination and immunisation was 55.2%.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Castlefields10365.868.5%60.8%82.8%
    Brookvale Practice11468.259.9%76.2%78.9%
    Grove House12133.644.5%67.8%72.4%
    Weaver Vale11170.048.2%58.5%67.3%
    Tower House10927.245.3%72.7%65.5%
    Murdishaw10448.831.9%75.6%59.4%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNHalton (LAD)AssetPCNHalton (LAD)
    Care homes (catchment)9 (293 beds)n/aSchools (catchment)69n/a
    Children's centres48Places of worship2655
    Libraries12Primary schools (LA maintained)1933
    Primary academies913Special schoolsn/a1

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Standardise annual asthma review recall

    Annual asthma reviews reach 64.0% (England 65.7%) across 5,342 patients (8.3% prevalence versus England 6.6%), leaving about 1,900 unreviewed alongside 2,628 youth asthma items per 1,000 (England 1,488). For discussion, practices could run a single recall template pairing inhaler prescribing checks with flexible after-school or holiday review slots. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Structured hypertension and statin recall

    Across 12,139 hypertension patients (17.7%, England 15.2%), three-year gains trailed England in BP recording (+0.9% versus +3.6%) and target treatment (+0.6% versus +3.6%), with diabetic statin coverage at 66.7% (England 73.2%). For discussion, pharmacist-led clinics could check overdue blood pressures, escalate antihypertensives and review statins for diabetic patients. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Pre-school MMR2 and booster recall

    At age 5 (cohort 159), MMR coverage drops 5 pp from dose 1 (96.2%) to dose 2 (91.2%, 3.8 pp below the 95.0% target), with 4-in-1 booster coverage at 90.6%. Low cost, quick to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older adult care reviews (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Dual track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI health check coordination (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension recall and titration audit (p5)Hypertension patients with a recent blood pressure readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Breast screening recall audit (p7)Breast screening coverage: aged 53 to 70 years old—PCN
    Option 1 · Standardise annual asthma review recall (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Structured hypertension and statin recall (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Pre-school MMR2 and booster recall (p12)MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% target · Core20PLUS5 · 10YHP equity testPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15